1 Recursion Pharmaceuticals Inc Receivables Turnover Ratio (RXRX), from the third quarter 2026 to the third quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Recursion Pharmaceuticals Inc   (NASDAQ: RXRX)
 

Recursion Pharmaceuticals Inc Accounts Receivables Turnover Ratio from the third quarter 2026 to the third quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Recursion Pharmaceuticals Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2026 to a ratio of 3.15, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the third quarter 2026. Average receivable collection period, for the Recursion Pharmaceuticals Inc in Sep 30 2026 quarter, has decreased to 116 days, compared to 124 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector Recursion Pharmaceuticals Inc achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Recursion Pharmaceuticals Inc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RXRX Receivables Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Receivable Change 55.48 % -33.38 % -70.55 % -49.87 % 871.62 %
Y / Y Revenue Change 258.49 % -60.1 % -56.11 % 681.74 % -80.16 %
Receivable Turnover Ratio (TTM) 3.15 2.94 3.25 2.61 1.26
RXRX's Total Ranking # # # # #
Accounts Receivable average collection period days 116 124 112 140 290
Seq. Receivable Change 136.68 % 5.95 % -44.89 % 12.5 % 1.41 %
Seq. Revenue Change 141.88 % 18.51 % -81.79 % 586.72 % -73.08 %


Receivable Turnover Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #

Receivable Turnover Ratio Statistics
High Average Low
0 0 0
 





RXRX Company Profile • Back to RXRX Efficiency Comparisons • Compare RXRX Receivables Turnover Ratio to its Competitors

Financial Statements
Recursion Pharmaceuticals Inc 's Accounts Receivable $ 34 Millions Visit RXRX's Balance sheet
Recursion Pharmaceuticals Inc 's Sales TTM $ 68 Millions Visit RXRX's Income Statement
Sources of RXRX's Revenues Visit RXRX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RXRX's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RXRX's Growth Rates RXRX's Roa RXRX's Inventory Turnover Ratio RXRX's Dividend Comparisons
RXRX's Profitability Ratios RXRX's Roi RXRX's Asset Turnover Ratio RXRX's Dividend Growth
RXRX's Valuation Ratios RXRX's Roe RXRX's Financial Strength Ratios RXRX's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Sep 30 2026 Receivable at quarter ending Sep 30 2026
Emergent Biosolutions Inc   5.49 $ 649.100  Millions$ 118.325  Millions
Alnylam Pharmaceuticals Inc   5.48 $ 5,013.242  Millions$ 914.792  Millions
Johnson and Johnson  5.45 $ 99,335.000  Millions$ 18,233.000  Millions
Viskase Holdings inc   5.43 $ 271.837  Millions$ 50.050  Millions
Incyte Corporation  5.42 $ 6,010.754  Millions$ 1,109.534  Millions
Integer Holdings Corporation  5.38 $ 1,825.122  Millions$ 339.414  Millions
Ardelyx inc   5.37 $ 468.220  Millions$ 87.120  Millions
Ptc Therapeutics inc   5.26 $ 1,155.554  Millions$ 219.663  Millions
Repligen Corp  5.21 $ 805.610  Millions$ 154.771  Millions
Biomerica Inc   5.17 $ 4.338  Millions$ 0.838  Millions
Indivior Pharmaceuticals Inc   5.14 $ 1,376.000  Millions$ 267.500  Millions
Ge Healthcare Technologies Inc   5.11 $ 19,878.000  Millions$ 3,886.750  Millions
Abbvie Inc   5.04 $ 66,014.000  Millions$ 13,100.250  Millions
West Pharmaceutical Services Inc   5.00 $ 3,397.100  Millions$ 680.050  Millions
Aquestive Therapeutics Inc   4.98 $ 48.837  Millions$ 9.803  Millions
Pfizer Inc  4.98 $ 63,625.000  Millions$ 12,785.250  Millions
Omniab Inc   4.88 $ 40.211  Millions$ 8.233  Millions
Mirum Pharmaceuticals Inc   4.81 $ 670.778  Millions$ 139.538  Millions
Bristol myers Squibb Company  4.77 $ 50,033.000  Millions$ 10,493.500  Millions
Bausch and Lomb Corp  4.68 $ 5,418.000  Millions$ 1,158.500  Millions
Orthopediatrics Corp  4.61 $ 263.665  Millions$ 57.191  Millions
Cryo cell International Inc   4.54 $ 31.127  Millions$ 6.851  Millions
Neurocrine Biosciences Inc   4.49 $ 3,701.700  Millions$ 824.800  Millions
Glaukos Corp  4.47 $ 578.355  Millions$ 129.301  Millions
Bioventus Inc   4.46 $ 585.319  Millions$ 131.366  Millions
Eli Lilly And Company  4.41 $ 86,462.000  Millions$ 19,590.250  Millions
Supernus Pharmaceuticals inc   4.35 $ 865.106  Millions$ 199.089  Millions
Stoke Therapeutics Inc   4.32 $ 28.211  Millions$ 6.527  Millions
Dexcom Inc   4.30 $ 5,104.900  Millions$ 1,187.150  Millions
Organon and Co   4.30 $ 6,111.000  Millions$ 1,421.750  Millions

Date modified: 2026-11-03T10:54:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.